Understanding the Expanding Role of Biosimilars in Quality Cancer Care

Understanding the Expanding Role of Biosimilars in Quality Cancer Care

Saturday, June 3, 2017 in Chicago, IL
Dinner -- Radisson Blu, 6:30 PM CT

Agenda

Welcome and Program Overview
Gary H. Lyman, MD, MPH, FASCO, FRCP (Edin)
Program Chair

Biosimilars in Oncology: Insights Into the Development and Evaluation Process
Rowena N. Schwartz, PharmD, BCOP

Landscape of Biosimilars in Supportive and Therapeutic Cancer Care
Jeffrey Crawford, MD

Integrating Biosimilars Into Oncology Practice
Gary H. Lyman, MD, MPH, FASCO, FRCP (Edin)

  • Benefits of Biosimilars
  • Key Prescribing Issues
  • Dispelling Common Misconceptions

 Panel Discussion and Final Thoughts

Faculty

Program Chair
Gary Lyman, MD, MPH, FASCO, FRCP (Edin)

Co-Director, Hutchinson Institute for Cancer
Outcomes Research (HICOR)
Public Health Sciences and Clinical Research
Divisions
Fred Hutchinson Cancer Research Center
Professor of Medicine/Medical Oncology
University of Washington School of Medicine
Seattle, Washington

Faculty
Jeffrey Crawford, MD

George Barth Geller Professor of Medicine
Duke University
Co-Director, Solid Tumor Therapeutics Program
Duke Cancer Institute
Durham, North Carolina

Faculty
Rowena Schwartz, PharmD, BCOP

Associate Professor
University of Cincinatti
Cincinatti, Ohio

CME

Goal Statement
The goal of this activity is to increase participants’ competence in describing the regulatory approval process for biosimilars and effectively using them to replace reference products in the daily practice of treating cancer.

Target Audience
This program is intended for medical oncologists and other healthcare professionals, including nurses, nurse practitioners, physician assistants, and pharmacists, who provide medical care for patients with cancer.

Learning Objectives

  • Describe potential differences between biosimilars and reference biologics in terms of their structure, function, regulatory requirements for approval, and data required to demonstrate biosimilarity, and the potential to increase access to biologic medications for cancer patients
  • Discuss key clinical considerations associated with the use of biosimilars in oncology, including extrapolation, immunogenicity, pharmacovigilance, and patient communication
  • Evaluate recent experiences and emerging clinical trial data regarding the safety and efficacy of biosimilars for supportive and therapeutic cancer care to aid informed decision making of safe integration into clinical practice
  • Identify benefits and address key misconceptions/myths that have arisen around biosimilar development and use in oncology practice

Accreditation

Physician Continuing Medical Education
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of National Comprehensive Cancer Network (NCCN) and Clinical Care Options, LLC.

NCCN is accredited by the ACCME to provide continuing medical education for physicians.

NCCN designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education
National Comprehensive Cancer Network (NCCN) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

NCCN designates this educational activity for a maximum of 2.0 contact hours.

Pharmacists
National Comprehensive Cancer Network (NCCN) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. NCCN designates this knowledge-based continuing education activity for 2 contact hours (0.2 CEUs) of continuing education credits (Universal Activity Number: 0836-9999-17-051-L01-P

Attention Pharmacists:

You must complete the post-test and evaluation within 30 days of the activity.  Continuing pharmacy education credit is reported to CPE Monitor once the post-test and evaluation are completed.  Before completing these requirements, be sure your NCCN profile has been updated with your NABP e-profile ID and date of birth or your credit can NOT be reported.  If you have not already done so, please complete your e-profile at http://www.nabp.net/ to obtain your NABP e-Profile ID.

DISCLOSURE OF UNLABELED USE  
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. NCCN and Clinical Care Options, LLC do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of NCCN and Clinical Care Options, LLC. Please refer to the official prescribing information for each product for discussion of approved indication, contraindications, and warnings. 

LEARNER’S BILL OF RIGHTS  
National Comprehensive Cancer Network (NCCN) recognizes that you are a lifelong learner who has chosen to engage in continuing education to identify or fill a gap in knowledge, skill, or performance. As part of NCCN’s duty to you as a learner, you have the right to expect that your continuing education experience with NCCN includes content that: 

  • Promotes improvements or quality in healthcare;
  • Is valid, reliable, and accurate;
  • Offers balanced presentations that are free of commercial bias for or against a product/service;
  • Is vetted through a process that resolves any conflicts of interests of planners, faculty, or authors;
  • Is driven and based on learning needs, not commercial interests;
  • Addresses the stated objectives or purpose; and
  • Is evaluated for its effectiveness in meeting the identified educational need.

A learning environment that:

  • Supports learners’ ability to meet their individual needs;
  • Respects and attends to any special needs of the learners;
  • Respects the diversity of groups of learners; and
  • Is free of promotional, commercial, and/or sales activities. 

Disclosure of:

  • Relevant financial relationships planners, faculty, and authors have with commercial interests related to the content of the activity and
  • Commercial support (funding or in-kind resources) of the activity